Page last updated: 2024-09-03

omega-n-methylarginine and ticlopidine

omega-n-methylarginine has been researched along with ticlopidine in 1 studies

Compound Research Comparison

Studies
(omega-n-methylarginine)
Trials
(omega-n-methylarginine)
Recent Studies (post-2010)
(omega-n-methylarginine)
Studies
(ticlopidine)
Trials
(ticlopidine)
Recent Studies (post-2010) (ticlopidine)
4,41134433610,2891,8934,671

Protein Interaction Comparison

ProteinTaxonomyomega-n-methylarginine (IC50)ticlopidine (IC50)
Alpha-2A adrenergic receptorHomo sapiens (human)0.382
Cytochrome P450 2D6Homo sapiens (human)6.2928
Alpha-2B adrenergic receptorHomo sapiens (human)0.304
Alpha-2C adrenergic receptorHomo sapiens (human)1.175
Cytochrome P450 2B6Homo sapiens (human)0.405
Cytochrome P450 2C19Homo sapiens (human)0.6678
Sigma non-opioid intracellular receptor 1Homo sapiens (human)0.426

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Baldus, S; Böger, R; Heitzer, T; Karstens, M; Meinertz, T; Ortak, M; Rudolph, V; Schwedhelm, E; Sydow, K; Tschentscher, P1

Trials

1 trial(s) available for omega-n-methylarginine and ticlopidine

ArticleYear
Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects.
    Arteriosclerosis, thrombosis, and vascular biology, 2006, Volume: 26, Issue:7

    Topics: Acetylcholine; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspirin; Biological Availability; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Endothelium, Vascular; Enzyme Inhibitors; Humans; Middle Aged; Nitric Oxide; omega-N-Methylarginine; Ticlopidine; Vasodilation; Vasodilator Agents

2006